Tuesday, June 9, 2009

Direct Comparison Study Between Diabetes Drugs

The Lancet Publishes Direct Comparison Study Between Diabetes Drugs liraglutide and exenatide

The Lancet published online the results of the LEAD™ 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with liraglutide had a statistically greater drop in HbA1c than those who received exenatide.

The study compared liraglutide, a human GLP-1 analogue, which is under investigation as a treatment for type 2 diabetes, to exenatide, the currently marketed GLP-1 receptor agonist.

0 comments:

Post a Comment

Corpo News Blog Archive